RXRX Stock jumps after JPMorgan upgrade and trial data boost, fueling investor optimism in Recursion’s AI drug discovery ...

Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...

The native just-in-time compiler in Python 3.15 can speed up code by as much as 20% or more, although it’s still experimental ...

The simulation hypothesis—the idea that our universe might be an artificial construct running on some advanced alien computer ...

Here are seven biopharma-related trends for 2026 that have emerged from GEN interviews with experts and other industry stakeholders, and from reviews of reports and public statements.

In 2025, Anthropic will grow from $1 billion to $9 billion in ARR (annual recurring revenue). OpenAI, meanwhile, will go from ...

Skills—a capability that allows users to teach Claude repeatable workflows—was introduced in October, and now Anthropic is ...

Three recent graduates from the MSU photo program noticed a glaring gap in the photo-journal world. While there has been ...

Cornered in a part of Downtown Los Angeles swamped in contemporary art museums and performance centers, REDCAT has become a ...

Since the 2000s, Google Search—and later YouTube and Discover—served as the primary discovery and monetization engines for ...